Oral Transmucosal Drug Market

ID: MRFR/Pharma/40636-HCR
200 Pages
Rahul Gotadki
Last Updated: April 15, 2026
Oral Transmucosal Drug Market Research Report By Drug Type (Buprenorphine, Fentanyl, Midazolam, Nitroglycerin, Other Analgesics), By Formulation Type (Lozenges, Films, Tablets, Sprays), By Therapeutic Area (Pain Management, Anesthesia, Cardiovascular, Neurological Disorders), By Route of Administration (Sublingual, Buccal) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Oral Transmucosal Drug Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.94%
2024 Market Size$ 5.73 Billion
2025 Market Size$ 6.13 Billion
2035 Market Size$ 11.99 Billion
Key Players
Purdue Pharma
Mylan
Teva Pharmaceuticals
AstraZeneca
Johnson & Johnson
Boehringer Ingelheim
Trends
  • Rising Demand for Non-Invasive Drug Delivery
  • Technological Innovations in Formulations
  • Regulatory Support for Novel Therapies
Opportunities
  • Rising Demand for Rapid Onset of Action
  • Increasing Prevalence of Chronic Diseases
  • Advancements in Drug Formulation Technologies
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Type (USD Billion) | |
      1. 4.1.1 Buprenorphine | |
      2. 4.1.2 Fentanyl | |
      3. 4.1.3 Midazolam | |
      4. 4.1.4 Nitroglycerin | |
      5. 4.1.5 Other Analgesics |
    2. 4.2 Healthcare, BY Formulation Type (USD Billion) | |
      1. 4.2.1 Lozenges | |
      2. 4.2.2 Films | |
      3. 4.2.3 Tablets | |
      4. 4.2.4 Sprays |
    3. 4.3 Healthcare, BY Therapeutic Area (USD Billion) | |
      1. 4.3.1 Pain Management | |
      2. 4.3.2 Anesthesia | |
      3. 4.3.3 Cardiovascular | |
      4. 4.3.4 Neurological Disorders |
    4. 4.4 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.4.1 Sublingual | |
      2. 4.4.2 Buccal |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Purdue Pharma (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Mylan (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Teva Pharmaceuticals (IL) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AstraZeneca (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Johnson & Johnson (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Boehringer Ingelheim (DE) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 AbbVie (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 GSK (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG TYPE |
    7. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE |
    8. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA |
    9. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
    13. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
    18. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    19. 6.16 UK MARKET ANALYSIS BY DRUG TYPE |
    20. 6.17 UK MARKET ANALYSIS BY FORMULATION TYPE |
    21. 6.18 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
    22. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    23. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
    26. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    30. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    31. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
    34. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    35. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
    38. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    47. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    48. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    51. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    52. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
    55. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    64. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
    67. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    71. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
    80. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    81. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
    84. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Oral Transmucosal Drug Market Segmentation

Oral Transmucosal Drug Market By Drug Type (USD Billion, 2025-2035)

  • Buprenorphine
  • Fentanyl
  • Midazolam
  • Nitroglycerin
  • Other Analgesics

Oral Transmucosal Drug Market By Formulation Type (USD Billion, 2025-2035)

  • Lozenges
  • Films
  • Tablets
  • Sprays

Oral Transmucosal Drug Market By Therapeutic Area (USD Billion, 2025-2035)

  • Pain Management
  • Anesthesia
  • Cardiovascular
  • Neurological Disorders

Oral Transmucosal Drug Market By Route of Administration (USD Billion, 2025-2035)

  • Sublingual
  • Buccal

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.